Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-roche-provides-initial-update-from-phase-iib-trial-in-alzheimers-disease-5293
Evotec AG reports results of first quarter 2015
– VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE – MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED Hamburg, Germany – 12 May 2015: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2015-5285
Facio partners with Evotec and initiates FSHD drug discovery programme
Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/facio-partners-with-evotec-and-initiates-fshd-drug-discovery-programme-5281
Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery
Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/asahi-kasei-pharma-selects-evotec-as-its-partner-for-ion-channel-drug-discovery-5279
Evotec FY 2014: Strong performance in EVT Execute and acceleration of EVT Innovate
Evotec AG today announced its financial results for the fiscal year ended 31 December 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2014-strong-performance-in-evt-execute-and-acceleration-of-evt-innovate-5275
Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-sign-definitive-agreement-for-major-multi-component-strategic-alliance-5273
Second Genome and Evotec to collaborate in microbiome discovery and development
Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/second-genome-and-evotec-to-collaborate-in-microbiome-discovery-and-development-5269
Evotec and C4XD enter collaboration to identify pre-clinical development candidates for stress-related addictive disorder programme
Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD’s unique NMR technology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-c4xd-enter-collaboration-to-identify-pre-clinical-development-candidates-for-stress-related-addictive-disorder-programme-5265
Evotec achieves further milestones in TargetAD collaboration with Janssen
Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec’s TargetAD database and for the transition of targets into the drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-further-milestones-in-targetad-collaboration-with-janssen-5263
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration
Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-padlock-therapeutics-announce-initial-success-and-extension-of-long-term-collaboration-5261